Profitelligence Profitelligence · Filing Ledger Open RVMD research →

Form 8-K · Current Report · Filed 2025-06-27

Revolution Medicines Announces Voting Results from Annual Meeting

Revolution Medicines, Inc. reported the voting results from its 2025 Annual Meeting of Stockholders held on June 26, 2025. The election of four Class II directors, ratification of PricewaterhouseCoopers LLP as the independent auditors, and the advisory approval of executive compensation were approved by the stockholders. Detailed vote counts were provided for each proposal.

Filer
Revolution Medicines Inc. RVMD · NASDAQ
Filed
Accession
0001193125-25-151254
CIK
0001628171
Signal
Low impactHealthcare

Items reported

Item 5.07

Submission of Matters to a Vote of Security Holders

Director Elections Results Say-on-Pay Approved

Market reaction

Close before filing

$37.48

Next session

-1.8%

Since filing

+400.3%

Latest close

$187.53

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from RVMD reporting the same item, with the next session's move:

About Revolution Medicines Inc.

Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another RVMD filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts